“A likely scenario is there will be likely a need for a third dose somewhere between six and 12 months, and then from there there would be an annual revaccination,” Dr. Bourla said.
He said variants will play a key role in determining whether annual shots will be needed.
“It is extremely important to suppress the pool of people that can be susceptible to the virus because they are vaccinated with high-efficacy vaccines,” he said, according to The Hill.
Pfizer and its partner BioNTech have reported that their vaccine remained 91 percent effective six months after the second dose in a study.
David Kessler, MD, the White House’s chief science officer, told lawmakers April 15 that people “should expect” booster shots, but that officials “don’t know everything at this moment.”
Peter Marks, MD, PhD, the FDA’s director of the Center for Biologics Evaluation and Research, said officials believe protection from the vaccines will last at least nine months, The Hill reported.
Read the full article here.
More articles on pharmacy:
J&J vaccine pause continues: Why Fauci thinks it could be a good thing
Moderna vaccine 90% effective after 6 months, study shows
9 things to know about the J&J, AstraZeneca COVID-19 vaccines & blood clots
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.